Genitourinary cancer
CA244-0012
Randomised, open-label, phase 2/3 trial of izalontamab brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants on or after an immunotherapy-based treatment
Trial overview
Clinical Area
Medical Oncology
Disease
Urothelial
Disease site
Genitourinary (GU)
Study Phase
Phase II
Trial Identifiers
Registration number: NCT07106762
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries